Eli Lilly and Company
LLY
$1115.70
-0.65%
Eli Lilly & Co. is a global pharmaceutical leader focused on neuroscience, cardiometabolic, oncology, and immunology, with key products including Mounjaro, Zepbound, and Verzenio. The company has established itself as a dominant force in the rapidly expanding GLP-1 market for diabetes and obesity, leveraging its first-mover advantage and robust pipeline to outpace competitors like Novo Nordisk. Currently, investor attention is centered on Lilly's strategic expansion beyond metabolic diseases, highlighted by its $2.9 billion acquisition of Merida Biosciences to bolster immunology, and the recent FDA approval for Mounjaro to reduce cardiovascular risk in diabetes patients, which broadens its addressable market. The narrative is also shaped by intensifying competition in the obesity space, with rivals like Amgen and Novo Nordisk introducing novel dosing options, yet Lilly's diversified portfolio and clinical efficacy continue to drive its growth story.…
LLY
Eli Lilly and Company
$1115.70
Related headlines
Investment Opinion: Should I buy LLY Today?
Based on the analysis, LLY is rated a Buy. The thesis is that its exceptional revenue growth and margin expansion, coupled with a strong pipeline and strategic acquisitions, justify its premium valuation and offer significant upside potential. Analyst consensus is Buy with an average target of $1,315.56, implying 14.5% upside from the current price of $1,149.36.
Sign up to view all
LLY 12-Month Price Forecast
The AI assessment is bullish on LLY, given its exceptional growth metrics, strong profitability, and favorable valuation relative to growth. The stock's low beta of 0.506 provides some downside protection, while its market leadership in GLP-1 drugs offers a clear growth runway. However, competitive and regulatory risks could temper upside. The stance would be downgraded to neutral if revenue growth falls below 30% or if the forward PE exceeds 30x, and upgraded to strongly bullish if the stock pulls back to below $1,000 while fundamentals remain intact.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eli Lilly and Company's 12-month outlook, with a consensus price target around $1318.66 and implied upside of +18.2% versus the current price.
Average Target
$1318.66
0 analysts
Implied Upside
+18.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$930 - $1600
Analyst target range
Eli Lilly is covered by 29 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.7 (where 1 is Strong Buy and 5 is Sell). The average target price is $1,315.56, implying an upside of approximately 14.5% from the current price of $1,149.36. The analyst sentiment is overwhelmingly bullish, with recent actions from major firms like Citigroup, UBS, and Morgan Stanley all reiterating Buy or Overweight ratings in July 2026. The target price range spans from a low of $850.00 to a high of $1,600.00, reflecting a wide dispersion of expectations. The high target suggests analysts anticipate continued strong sales from Mounjaro and Zepbound, potential label expansions, and successful pipeline developments, while the low target may factor in competitive pressures from Novo Nordisk and Amgen, pricing concerns, or regulatory risks. The wide spread indicates high uncertainty about the sustainability of Lilly's growth, but the overall bullish consensus and recent positive catalysts, such as the FDA approval for Mounjaro and the Merida acquisition, support a favorable outlook.
Bulls vs Bears: LLY Investment Factors
Eli Lilly presents a compelling growth story with explosive revenue growth, expanding margins, and a robust pipeline, but trades at a significant premium to peers. The bull case is supported by strong fundamentals and analyst optimism, while the bear case highlights competitive and valuation risks. Currently, the bull side has stronger evidence given the accelerating growth and profitability, but the key tension is whether LLY can sustain its growth trajectory amid intensifying competition and maintain its premium valuation. The resolution of this tension will determine if the stock can reach analyst targets or face a de-rating.
Bullish
- Explosive Revenue Growth: Q1 2026 revenue surged 55.55% YoY to $19.80B, accelerating from 21.7% growth in Q1 2025, driven by Mounjaro and Zepbound. This rapid acceleration underscores strong demand for its GLP-1 portfolio and expanding market share.
- Exceptional Profitability Expansion: Net margin jumped to 37.36% in Q1 2026 from 21.68% a year ago, with operating margin at 44.70%. This reflects significant operating leverage and pricing power, boosting EPS to $8.27 from $3.07.
- Undervalued on PEG Ratio: PEG ratio of 0.49 suggests the stock is undervalued relative to its growth rate, despite a trailing PE of 46.73x. Forward PE of 24.32x indicates market expects substantial earnings growth, which is supported by analyst EPS estimates of $66.16 for 2026.
- Strong Analyst Conviction: Consensus rating is Buy with a mean score of 1.7, and average target price of $1,315.56 implies 14.5% upside. Recent reiterations from Citigroup, UBS, and Morgan Stanley in July 2026 reinforce bullish sentiment.
Bearish
- Premium Valuation to Peers: Trailing PE of 46.73x is more than double the industry average of 22x, and PS ratio of 14.81x is extremely high. This leaves little room for error; any growth disappointment could trigger multiple compression.
- Intense Competitive Threats: Novo Nordisk's implant partnership and Amgen's once-monthly MariTide could disrupt LLY's market share in obesity. These competitors offer convenience advantages that may erode LLY's pricing power and growth trajectory.
- High Debt Levels: Debt-to-equity ratio of 1.60 is elevated, though manageable given strong cash flow. However, rising interest expenses ($332M in Q1 2026) and potential future acquisitions could strain balance sheet if growth slows.
- Regulatory and Pricing Risks: Potential drug pricing reforms or reimbursement changes for GLP-1 drugs could pressure margins. Recent news highlights scrutiny on drug costs, and any adverse policy shifts could impact revenue growth.
LLY Technical Analysis
Eli Lilly's stock has demonstrated a robust long-term uptrend, with a 1-year price change of +54.71%, significantly outperforming the S&P 500's +18.65% over the same period. Currently trading at $1,149.36, the stock sits at approximately 89% of its 52-week range (low of $712.05, high of $1,292.65), indicating it remains closer to the highs, reflecting strong momentum but also potential overextension. The stock's beta of 0.506 suggests it is less volatile than the broader market, which may appeal to risk-averse investors despite its high valuation.
Beta
0.50
0.50x market volatility
Max Drawdown
-23.3%
Largest decline past year
52-Week Range
$712-$1293
Price range past year
Annual Return
+47.5%
Cumulative gain past year
| Period | LLY Return | S&P 500 |
|---|---|---|
| 1m | -8.6% | -1.1% |
| 3m | -1.5% | +3.0% |
| 6m | +13.3% | +15.4% |
| 1y | +47.5% | +16.2% |
| ytd | +3.3% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LLY Fundamental Analysis
Eli Lilly's revenue trajectory is exceptionally strong, with Q1 2026 revenue of $19.80 billion, representing a 55.55% year-over-year growth rate, accelerating from the 21.7% growth seen in Q1 2025. This growth is driven by its cardiometabolic portfolio, which generated $15.76 billion in revenue, led by blockbuster drugs Mounjaro and Zepbound, while oncology contributed $2.27 billion and immunology $1.20 billion. The company's profitability is equally impressive, with Q1 2026 net income of $7.40 billion and a net margin of 37.36%, up from 21.68% in the year-ago quarter, reflecting operating leverage and pricing power. Gross margins remain high at 81.93%, and operating margins expanded to 44.70%, indicating efficient cost management despite increased R&D spending of $3.51 billion. Lilly's balance sheet is solid, with a current ratio of 1.58 and a debt-to-equity ratio of 1.60, which is manageable given its strong cash generation; free cash flow for the trailing twelve months reached $13.58 billion, and Q1 2026 operating cash flow was $5.33 billion, comfortably covering capital expenditures of $2.33 billion and dividends of $1.55 billion.
Quarterly Revenue
$19.8B
2026-03
Revenue YoY Growth
+55.5%
YoY Comparison
Gross Margin
81.9%
Latest Quarter
Free Cash Flow
$13.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LLY Overvalued?
Given Eli Lilly's positive net income, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE stands at 46.73x, while the forward PE is 24.32x, indicating that the market expects significant earnings growth, which is supported by a PEG ratio of 0.49, suggesting the stock is undervalued relative to its growth rate. Compared to the industry average PE of 22x, Lilly trades at a substantial premium, but this is justified by its superior growth and profitability, as evidenced by its 55.55% revenue growth and 37.36% net margin, far exceeding sector norms. Historically, Lilly's PE has ranged from 27.8x to 205.1x over the past three years, with the current trailing PE of 46.73x sitting below the midpoint, indicating that the stock is not at extreme valuation levels despite its recent run-up.
PE
46.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 28x~76x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
35.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high debt-to-equity ratio of 1.60, which could become problematic if cash flows weaken, and a payout ratio of 26.09% that may limit dividend growth. However, strong free cash flow of $13.58B TTM and a current ratio of 1.58 provide liquidity cushion. Margin pressure could arise from increased competition and R&D spending, which rose to $3.51B in Q1 2026, potentially impacting net margins if revenue growth decelerates. Revenue concentration in cardiometabolic drugs (Mounjaro, Zepbound) exposes LLY to any negative clinical or regulatory news for this class, as seen with potential safety concerns or pricing actions.
FAQ
The key risks are: 1) Competitive pressure from Novo Nordisk and Amgen, which could erode market share in the obesity market. 2) Regulatory risks, including potential drug pricing reforms that could impact revenue. 3) Valuation risk, as the stock trades at a premium PE of 46.73x, making it vulnerable to multiple compression if growth slows. 4) Financial risk from high debt levels (D/E 1.60), though cash flow is strong. The most severe risk is a combination of competitive and regulatory setbacks, which could lead to a -38% decline to the 52-week low of $712.05.
The 12-month forecast is bullish, with a base case target of $1,200-$1,400 (50% probability), aligning with the analyst average of $1,315.56. The bull case targets $1,400-$1,600 (30% probability) if growth accelerates, while the bear case targets $850-$1,000 (20% probability) if competitive or regulatory risks materialize. The most likely scenario is the base case, assuming revenue growth remains above 40% and margins stay stable. Investors should monitor quarterly earnings and competitive developments to adjust expectations.
Based on trailing PE of 46.73x, LLY is overvalued compared to the industry average of 22x. However, its forward PE of 24.32x and PEG ratio of 0.49 suggest it is undervalued relative to its expected growth. The market is pricing in significant future earnings growth, which is supported by analyst estimates of $66.16 EPS for 2026. Historically, LLY's PE has ranged from 27.8x to 205.1x, and the current level is below the midpoint, indicating it is not at extreme levels. Overall, the valuation is justified by its superior growth and profitability, but it leaves little room for error.
LLY is a good buy for investors seeking high growth, given its 55.55% revenue growth and 37.36% net margin. Analyst consensus is Buy with a 14.5% upside to the average target of $1,315.56. However, the stock trades at a premium valuation (PE 46.73x), so it is sensitive to any growth disappointment. It is best suited for investors with a high risk tolerance and a long-term horizon, as competitive and regulatory risks could cause volatility. For those, the current price offers a reasonable entry point, but for value investors, waiting for a pullback below $1,000 might be prudent.
LLY is more suitable for long-term investment due to its high growth stage, with revenue growing 55.55% YoY and a beta of 0.506, which provides some stability. The stock has low dividend yield (0.56%), so it is not for income seekers. Earnings visibility is high given the strong demand for GLP-1 drugs, but short-term volatility is possible due to news flow. A minimum holding period of 3-5 years is recommended to fully capture the growth potential of its pipeline and market expansion. Short-term traders may find opportunities, but the stock's high valuation makes it risky for quick trades.